Allurion Technologies Inc.(ALUR)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Allurion Technologies faces a critical inflection point as its core weight-loss device business struggles against the rapid market adoption of GLP-1 pharmaceuticals, resulting in a 47.2% year-over-year revenue decline in 2026Q1.
• The company's financial position appears increasingly precarious, characterized by a negative equity position of $77.9 million and an operating margin of -126.6% that suggests the current business model lacks the necessary scale to achieve profitability.
• Investors should monitor the company's ability to manage its $29.4 million debt load against a dwindling cash balance of only $5.1 million, which may necessitate further dilutive capital raises to sustain operations.